In recent years, research on Alzheimer's disease has become one of the most intensely pursued areas in the field of neuroscience. Despite the wealth of information gathered, however, relatively little of what has been learned has resulted in the development of effective treatments.
Pharmacological Treatment of Alzheimer's Disease: Molecular and Neurobiological Foundations gathers the top investigators in the area of Alzheimer's research and presents their pioneering work on potential treatments for this devastating disease. Combining current knowledge of the neurobiology of memory with molecular studies related to disease etiology, this book provides a comprehensive review of the latest research on Alzheimer's as well as a thorough examination of current experiments with drugs that could correct the biochemical defects that cause Alzheimer's or ameliorate the associated cognitive deficits. Each of the book's three sections, "Neurobiology of Cognition," "Molecular Aspects of Alzheimer's Disease," and "Alzheimer's Drug Discovery and Development," is a collection of the most recent studies by prominent specialists in their respective fields.
Among the numerous topics covered:
* Structure and dynamics of multiple memory systems in Alzheimer's disease
* Interaction of neuromodulatory systems regulating memory storage
* Neuropsychological features of Alzheimer's disease
* Normal brain aging and Alzheimer's disease pathology
* Recent developments in the genetics of Alzheimer's disease
* Animal models relevant to Alzheimer's disease
* Considerations for clinical trials in Alzheimer's disease
* A fundamental role for estrogens in cognition andneuroprotection
* Alzheimer's disease: prospects for treatment in the next decade.
A comprehensive and balanced overview of the most critically important information available, Pharmacological Treatment of Alzheimer's Disease: Molecular and Neurobiological Foundations heralds a new phase in the process of studying this uniquely human disease: the search for treatments. It is must reading for neuroscientists, pharmacologists, medicinal chemists, and academic physicians involved in basic research and clinical trials, as well as for clinicians who treat Alzheimer's patients.